乳腺癌放疗野和靶区与手臂引流淋巴结位置的关系
研究纳入18例乳腺癌患者,对侧手臂行淋巴显像和SPECT CT,勾画手臂引流淋巴结(ARM淋巴结)并按ESTRO指南勾画对侧乳腺和腋窝,生成两种切线IMRT计划(50 Gy/25次)。全乳放疗计划中仅5/18个ARM淋巴结在野内,全乳加腋窝计划中18/18个均在野内且均>40 Gy。作者结论为多数ARM淋巴结(72%)在全乳切线野外,需前瞻性研究评估保留ARM淋巴结的腋窝放疗的肿瘤学安全性。
要点
- 全乳切线放疗计划中仅5/18个ARM淋巴结在野内,仅2个接受超过40 Gy。
- 全乳加腋窝(1-4站)计划中18/18个ARM淋巴结均在野内且均超过40 Gy。
- 按EORTC共识完全遮挡肱骨头并未使ARM淋巴结免于照射。
核心结论
- 作者结论为绝大多数ARM淋巴结(72%)位于全乳切线放疗野外。
- 本研究中所有ARM淋巴结均位于按ESTRO勾画指南覆盖腋窝1-4站的腋窝放疗野内,按EORTC共识完全遮挡肱骨头未导致ARM淋巴结免于照射。
- 作者提出需前瞻性研究评估保留ARM淋巴结的腋窝放疗的肿瘤学安全性及其降低手臂淋巴水肿风险的潜力。
研究设计与样本
- 研究纳入18例乳腺癌患者,行对侧手臂(左10例、右8例)淋巴显像和SPECT CT扫描,扫描体位近似放疗体位。
- 用MIM软件在SPECT CT上勾画每例受试者的ARM淋巴结并由核医学医师核实,将CT部分转入ECLIPSE放疗计划系统,按ESTRO勾画指南勾画对侧乳腺和腋窝。
- 为每例受试者用标准切线IMRT技术生成两个放疗计划,剂量均为50 Gy分25次,一个仅治疗对侧乳腺,另一个治疗对侧乳腺加对侧腋窝1-4站。
- ARM淋巴结平均剂量超过处方剂量50%即25 Gy时视为「在放疗野内」。
主要发现
- 1例右侧受试者有2个ARM淋巴结,其余均有1个;全部ARM淋巴结(左10个、右9个)均位于腋窝1站。
- 对有2个ARM淋巴结的受试者,分析采用接受剂量较高的那个淋巴结。
- 全乳放疗计划中ARM淋巴结平均剂量范围为0.8至45.5 Gy,中位数10.9 Gy。
- 全乳加腋窝计划中ARM淋巴结平均剂量范围为43.4至52.5 Gy,中位数49.3 Gy。
- 全乳放疗计划中仅5/18个ARM淋巴结「在放疗野内」,仅2个ARM淋巴结接受超过40 Gy;全乳加腋窝计划中18/18个ARM淋巴结均「在放疗野内」且均接受超过40 Gy。
局限性
- 作者提出需前瞻性研究评估保留ARM淋巴结的腋窝放疗的肿瘤学安全性及其降低手臂淋巴水肿风险的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lymphoedema of the arm following axillary surgery or radiotherapy remains a significant side effect affecting some women after breast cancer treatment. Axillary reverse mapping (ARM) is a technique used to identify the lymph node draining the arm (ARM node). Our study aim was to examine the location of the ARM nodes in relation to target volumes and treatment fields for breast cancer radiotherapy. MATERIALS AND METHODS: Eighteen breast cancer patients underwent lymphoscintigraphy of contralateral arm (left 10, right 8) and SPECT CT scan on a research study. Patient position for the SPECT CT scan approximated the position used for radiotherapy. Using MIM software™, the ARM node for each subject was contoured on the SPECT CT and verified by a nuclear medicine physician. The CT component of the SPECT CT was then transferred to ECLIPSE™ radiotherapy planning software, and the contralateral breast and axilla were contoured on this CT scan according to the ESTRO contouring guideline. Two radiotherapy plans were generated for each subject using standard tangential IMRT technique at a dose of 50 Gy in 25 fractions, one treating contralateral breast alone, the other treating contralateral breast and contralateral axilla level 1-4. The ARM node was considered "within the radiotherapy field" if the mean dose received by the ARM node was more than 50% of the prescribed dose: i.e., 25 Gy. RESULTS: One right-sided subject had 2 ARM nodes, all others had 1 ARM node. All ARM nodes (left 10, right 9) were located within level 1 of the axilla. For the subject with 2 ARM nodes, the node that received a higher dose was used for the analysis. The mean dose received by the ARM node in the whole breast radiotherapy plans ranged from 0.8 to 45.5 Gy, with a median of 10.9 Gy. The mean dose received by the ARM node in the whole breast and axilla plans ranged from 43.4 to 52.5 Gy, with a median of 49.3 Gy. In the whole breast radiotherapy plans, only 5 out of 18 ARM nodes were found to be "within radiotherapy field", and only 2 ARM nodes received more than 40 Gy. In the breast and axilla plans, all 18 ARM nodes were "within radiotherapy field" and all received more than 40 Gy. To better visualise the locations of ARM nodes, all left sided ARM nodes were then mapped onto a CT set from one of the left-sided subjects, and all the right sided ARM nodes mapped onto one of the right-sided subjects, and digitally reconstructed radiograph (DRR) for radiotherapy fields were produced. CONCLUSIONS: Our study demonstrates that the vast majority of ARM nodes (72%) are outside the tangential whole breast radiotherapy fields. In our study, all the ARM nodes were within the axillary radiotherapy fields covering level 1-4 axillary volumes according to the ESTRO contouring guideline, and complete shielding of the humeral head according to the EORTC consensus did not lead to sparing of the ARM nodes. A prospective study is needed to examine the oncological safety of ARM node-sparing axillary radiotherapy and its potential to reduce the risk of arm lymphoedema.
引用
- Wang W, Ward R, Jia D, et al. Location of arm draining lymph node in relation to breast cancer radiotherapy field and target volume. Radiother Oncol. 2018. PMID: 30446320. doi:10.1016/j.radonc.2018.10.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。